VH032-cyclopropane-F is primarily utilized in the field of medicinal chemistry and drug development. Its application is centered around its role as a key intermediate in the synthesis of targeted protein degraders, particularly proteolysis-targeting chimeras (PROTACs). These molecules are designed to selectively degrade disease-causing proteins by harnessing the cell's natural ubiquitin-proteasome system. The compound's structure, featuring a cyclopropane ring, enhances its binding affinity and stability, making it a valuable component in the development of novel therapeutic agents. Its use is particularly significant in oncology research, where it aids in the creation of drugs that can effectively target and eliminate proteins involved in cancer progression. Additionally, it is explored in the study of neurodegenerative diseases and other conditions driven by aberrant protein activity.